Tirzepatide, branded as Mounjaro®, is the first dual GIP/GLP-1 receptor agonist developed for Type 2 Diabetes (T2D), approved by the FDA in 2022. Its dual pathway provides superior HbA1c and weight reduction results compared to standard GLP-1 treatments. Clinical data, especially from SURPASS-4, show a reduced mortality rate in T2D patients compared to insulin glargine. With a favorable side-effect profile, Tirzepatide is well-positioned to become a leading therapy for T2D, while its dual action hints at future uses for related metabolic disorders, including obesity.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Mounjafei by Keifei Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
